Treatment of cholangiocarcinoma
AssigneeJanssen Pharmaceutica NV
InventorJacqueline Cirillo BUSSOLARI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating cholangio carcinoma in a patient comprising: evaluating a biological sample from the patient for the presence of one or more EGER mutants including at least the mutation FGFR3 R397C; or one or more EGER mutants including at least the mutation FGFR3 L608F; or one or more EGER mutants including at least the fusion FGFR2-TACC2; and treating the patient with an EGER inhibitor if one or more EGER mutants including at least the mutation FGFR3 R397C; or one or more EGER mutants including at least the mutation FGFR3 L608F; or one or more EGER mutants including at least the fusion FGFR2-TACC2 are present in the sample.
Claims19
A method of treating cholangiocarcinoma in a patient comprising:
- evaluating a biological sample from the patient for the presence of one or more FGFR mutants including at least the mutation FGFR3 R397C;
- or one or more FGFR mutants including at least the mutation FGFR3 L608F;
- or one or more FGFR mutants including at least the fusion FGFR2-TACC2;
- and treating the patient with an FGFR inhibitor if one or more FGFR mutants including at least the mutation FGFR3 R397C;
- or one or more FGFR mutants including at least the mutation FGFR3 L608F;
- or one or more FGFR mutants including at least the fusion FGFR2-TACC2 are present in the sample.
A method of treating cholangiocarcinoma in a patient harboring the mutation FGFR3 R397C;
- or harboring the mutation FGFR3 L608F;
- or harboring the fusion FGFR2-TACC2 comprising administering a FGFR inhibitor to said patient.
(canceled)
(canceled)
Dependencies are inferred from the claim text.